Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›MabThera 1400 mg concentrate for solution for infusion
Medicines register · Ireland

MabThera 1400 mg concentrate for solution for infusion

Authorisation EU/1/98/067/003 · Roche Registration GmbH

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Roche Registration GmbH (all products →)
Active substance
Rituximab
Clinical trials
256 clinical trials →
Dosage form
Solution for injection
Route of administration
Subcutaneous use
ATC code
L01XC02
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Rituximab: supply and approvals

14 authorised products on the HPRA list contain Rituximab. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 19 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 19 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 067. The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Rituximab in Ireland

13 other products on the HPRA list contain Rituximab, from 5 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Blitzima 100 mg concentrate for solution for infusionCelltrion Healthcare Hungary Kft.Centralised EU authorisationNot stated
Ituxredi 100 mg concentrate for solution for infusionReddy Holding GmbHCentralised EU authorisationNot stated
Ituxredi 500 mg concentrate for solution for infusionReddy Holding GmbHCentralised EU authorisationNot stated
MabThera 100 mg concentrate for solution for infusionRoche Registration GmbHCentralised EU authorisationNot stated
MabThera 1600 mg concentrate for solution for infusionRoche Registration GmbHCentralised EU authorisationNot stated
MabThera 500 mg concentrate for solution for infusionRoche Registration GmbHCentralised EU authorisationNot stated
Rixathon 100 mg concentrate for solution for infusionSandoz GmbHCentralised EU authorisationNot stated
Rixathon 500 mg concentrate for solution for infusionSandoz GmbHCentralised EU authorisationNot stated
Riximyo 100 mg concentrate for solution for infusionSandoz GmbHCentralised EU authorisationNot stated
Riximyo 500 mg concentrate for solution for infusionSandoz GmbHCentralised EU authorisationNot stated
Ruxience 100 mg concentrate for solution for infusionPfizer Europe MA EEIGCentralised EU authorisationNot stated
Ruxience 500 mg concentrate for solution for infusionPfizer Europe MA EEIGCentralised EU authorisationNot stated

All 14 products with Rituximab →

The licence holder

Roche Registration GmbH holds 90 products on the HPRA list, with 31 different active substances; 0 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.